Cargando…
Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production
A live-attenuated, human vaccine against mosquito-borne yellow fever virus has been available since the 1930s. The vaccine provides long-lasting immunity and consistent mass vaccination campaigns counter viral spread. However, traditional egg-based vaccine manufacturing requires about 12 months and...
Autores principales: | Nikolay, Alexander, Léon, Arnaud, Schwamborn, Klaus, Genzel, Yvonne, Reichl, Udo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153634/ https://www.ncbi.nlm.nih.gov/pubmed/30091043 http://dx.doi.org/10.1007/s00253-018-9275-z |
Ejemplares similares
-
MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation
por: Genzel, Yvonne, et al.
Publicado: (2010) -
High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells
por: Wu, Yixiao, et al.
Publicado: (2021) -
Cell culture-based production of defective interfering particles for influenza antiviral therapy
por: Wasik, Milena A., et al.
Publicado: (2017) -
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system
por: Vázquez-Ramírez, Daniel, et al.
Publicado: (2019) -
Performance of an acoustic settler versus a hollow fiber–based ATF technology for influenza virus production in perfusion
por: Gränicher, Gwendal, et al.
Publicado: (2020)